NICE back Roche’s Tecentriq for CDF
admin 1st November 2017 Uncategorised 0The National Institute for Health and Care Excellence is recommending Roche’s Tecentriq for use within the Cancer Drugs Fund to treat advanced urothelial cancer in certain circumstances.
More: NICE back Roche’s Tecentriq for CDF
Source: News